You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Veliparib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Veliparib?

Veliparib is an investigational drug.

There have been 96 clinical trials for Veliparib. The most recent clinical trial was a Phase 3 trial, which was initiated on April 2nd 2014.

The most common disease conditions in clinical trials are Carcinoma, Breast Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), AbbVie, and AbbVie (prior sponsor, Abbott).

Recent Clinical Trials for Veliparib
TitleSponsorPhase
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian CancerAbbViePhase 1
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)AHS Cancer Control AlbertaPhase 2
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast CancerFudan UniversityPhase 2

See all Veliparib clinical trials

Clinical Trial Summary for Veliparib

Top disease conditions for Veliparib
trials02468101214161820222426CarcinomaBreast NeoplasmsOvarian NeoplasmsNeoplasms[disabled in preview]
Top clinical trial sponsors for Veliparib
trials0510152025303540455055National Cancer Institute (NCI)AbbVieAbbVie (prior sponsor, Abbott)[disabled in preview]

See all Veliparib clinical trials

Development Update and Market Projection for Veliparib

Introduction to Veliparib

Veliparib, an investigational oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, has been a focal point in the oncology sector due to its potential in treating various types of cancer. Here, we delve into the development updates and market projections for this drug candidate.

Mechanism of Action

Veliparib works by inhibiting the PARP enzyme, which is crucial for DNA repair in cells. By preventing DNA repair in cancer cells, veliparib aims to enhance the effectiveness of DNA-damaging therapies such as chemotherapy and radiation. This mechanism is particularly promising in cancers with defects in homologous recombination repair, such as those with BRCA mutations[4].

Clinical Trials and Development

Phase 3 Trials Outcomes

Veliparib has undergone several Phase 3 clinical trials, but the results have been disappointing. In two late-stage trials, veliparib failed to meet its primary endpoints. One trial investigated veliparib in combination with chemotherapy (carboplatin and paclitaxel) for patients with advanced or metastatic squamous non-small cell lung cancer (NSCLC), particularly those with a history of smoking. The other trial focused on triple-negative breast cancer (TNBC) patients. In both cases, veliparib did not demonstrate significant improvements over the placebo group[1].

Previous Trials and Orphan Drug Designation

Despite the recent failures, veliparib had shown some promise in earlier trials. For instance, in the I-SPY 2 trial, a combination of veliparib with carboplatin and standard therapy showed a high predictive probability of delivering better outcomes for patients with triple-negative breast cancer. However, these benefits were not consistently observed across all patient subgroups[3].

Veliparib also received FDA Orphan Drug Designation for the treatment of advanced squamous NSCLC, recognizing the significant unmet need in this patient population[4].

Market Projections

Global PARP Inhibitors Market

The global PARP inhibitors market is expected to grow significantly over the next few years. As of 2023, the market size was valued at USD 8.97 billion and is projected to reach USD 21.44 billion by 2031, with a Compound Annual Growth Rate (CAGR) of 11.50%[2].

Competitive Landscape

Despite veliparib's recent setbacks, the PARP inhibitors market remains competitive and growing. Other PARP inhibitors like Lynparza (olaparib) from AstraZeneca, Rubraca (rucaparib) from Clovis Oncology, and Zejula (niraparib) from Tesaro have already gained market approval and are performing well. These drugs have set a high bar for new entrants, making it challenging for veliparib to gain traction unless it demonstrates significant efficacy in future trials[1].

Segmentation and Distribution

The PARP inhibitors market is segmented by drug type, indication, end users, and distribution channels. Veliparib, if approved, would compete in segments such as ovarian cancer, breast cancer, and non-small cell lung cancer. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies[5].

Future Prospects

Ongoing Research and Potential Indications

Veliparib is currently being studied in more than a dozen cancers, including advanced squamous and non-squamous NSCLC, ovarian cancer, and breast cancer. Although it has faced significant challenges, ongoing research may yet uncover new indications or combinations that could revitalize its development[4].

Regulatory and Market Challenges

The failure of veliparib in late-stage trials poses significant regulatory and market challenges. To regain momentum, AbbVie would need to present compelling new data or explore different therapeutic combinations that demonstrate clear clinical benefits.

Key Takeaways

  • Clinical Trials: Veliparib has failed to meet primary endpoints in recent Phase 3 trials for NSCLC and TNBC.
  • Market Projections: The global PARP inhibitors market is expected to grow to USD 21.44 billion by 2031, but veliparib's future is uncertain.
  • Competitive Landscape: Other PARP inhibitors have already gained market approval, setting a high bar for veliparib.
  • Future Prospects: Ongoing research in various cancer types may still uncover new opportunities for veliparib.

FAQs

What is veliparib and how does it work?

Veliparib is an investigational oral PARP inhibitor that works by preventing DNA repair in cancer cells, thereby enhancing the effectiveness of DNA-damaging therapies like chemotherapy and radiation.

What were the outcomes of the recent Phase 3 trials for veliparib?

The recent Phase 3 trials for veliparib failed to meet their primary endpoints in treating advanced or metastatic squamous NSCLC and triple-negative breast cancer.

What is the current market size and projection for the PARP inhibitors market?

The global PARP inhibitors market was valued at USD 8.97 billion in 2023 and is projected to reach USD 21.44 billion by 2031, with a CAGR of 11.50%.

Which other PARP inhibitors are currently on the market?

Other PARP inhibitors on the market include Lynparza (olaparib) from AstraZeneca, Rubraca (rucaparib) from Clovis Oncology, and Zejula (niraparib) from Tesaro.

What are the future prospects for veliparib?

Despite recent setbacks, veliparib is still being studied in various cancer types. Ongoing research may uncover new indications or therapeutic combinations that could revive its development.

Why did veliparib receive FDA Orphan Drug Designation?

Veliparib received FDA Orphan Drug Designation for the treatment of advanced squamous NSCLC due to the significant unmet need in this patient population.

Sources

  1. Biopharma Dive: AbbVie's PARP inhibitor fails two late-stage cancer trials
  2. Data Bridge Market Research: Global Poly (Adp-Ribose) Polymerase (PARP) Inhibitors Market
  3. OncLive: A Look at I-SPY 2: Novel Trial Design May Expand the Scope of Oncology Drug Development
  4. BioSpace: AbbVie Receives FDA Orphan Drug Designation For Investigational Medicine Veliparib
  5. Maximize Market Research: PARP Inhibitors Market - Industry Analysis and Forecast

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.